source
- [177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC[177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.onclive · 2mo ago↗ source
- FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid SarcomaThe FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma.onclive · 2mo ago↗ source
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.